

A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care

NCT06538064

Status RECRUITING
Sponsor Takeda
Enrollment 30 participants

Key Eligibility Criteria

Inclusion (9)

- Participants aged 18 years or older.
 - Investigator-confirmed documented diagnosis of CIDP of any type (e.g., typical, multifocal, focal, motor, sensory, or distal) according to the revised European Academy of Neurology and Peripheral Nerve Society (EAN/PNS) 2021 guidelines on the diagnosis and treatment of CIDP.
 - Participants must currently have a stable disease course (as per physician judgment) for at least 12 weeks.
 - Is considered a new user or current user of HyQvia-
 - New users (Cohort A) are participants on a CIDP treatment as of the date of enrollment, who intend to switch to HyQvia within 6 weeks after enrollment.
- ... and 4 more (see full listing online)

Exclusion (11)

- Had any HyQvia use, defined as
 - any record of HyQvia use prior to enrollment for new users of HyQvia (Cohort A), and
 - any record of HyQvia use more than 6 weeks preceding the enrollment date (the 6-week window may be extended depending on the recruitment progress) for current users of HyQvia (Cohort B).
 - Without any prior treatment for CIDP.
 - Pregnant or breastfeeding.
- ... and 6 more (see full listing online)

Locations (15 total)

Samir Macwan MD Inc, Rancho Mirage, California, United States
Neuro/Psych Sleep Clinic, San Francisco, California, United States
Yale School Of Medicine, New Haven, Connecticut, United States
... and 12 more locations